Silence Therapeutics (SLN) to Release Quarterly Earnings on Thursday

Silence Therapeutics (NASDAQ:SLN) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Silence Therapeutics Price Performance

Shares of NASDAQ SLN opened at $4.87 on Tuesday. Silence Therapeutics has a 1-year low of $4.06 and a 1-year high of $27.72. The company has a market cap of $149.64 million, a price-to-earnings ratio of -3.10 and a beta of 1.05. The stock’s 50-day moving average is $5.78 and its two-hundred day moving average is $12.07.

Analyst Ratings Changes

A number of research analysts have recently commented on SLN shares. Chardan Capital reiterated a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a report on Tuesday, December 10th. The Goldman Sachs Group initiated coverage on Silence Therapeutics in a research note on Tuesday, February 11th. They set a “sell” rating and a $6.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a research note on Wednesday, January 29th. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat, Silence Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $45.00.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.